The global anal fistula therapeutics market is estimated to grow at a CAGR of nearly 4.0% during the forecast period. Rising incidences of inflammatory bowel disease (IBD) is the major factor encouraging the demand for anal fistula therapeutics. As per the Centers for Disease Control and Prevention (CDC), in 2015, nearly 1.3% of the US adults (3 million) were reported being diagnosed with IBD...